Search results

This research aimed to investigate the information-seeking behaviour (ISB) and information needs of different professional groups within the pharmaceutical manufacturing sector in the Republic of Ireland (i.e. for what purpose information is acquired), the information sources professional groups use (including in-house documentation, regulations, industry guidelines, standards and colleagues) and the factors, which influence professional groups' choice of information sources. Furthermore, the research explored the perceived level of support that exists towards knowledge and information sharing.

A quantitative non-experimental research design, comprising of a self-completion survey questionnaire, was used to examine a number of information-seeking variables: information triggers, information sources and source influencers as well as information sharing enablers. It was related to four professional tasks: process technology/process development, regulatory support and quality/compliance support and engineering.

The research provides new insights into the ISB of pharmaceutical professionals working within a highly regulated and high-performance production environment, including a greater understanding of the context in which professional groups experience information needs. The levels of agreement observed in relation to employees' perception of information-sharing enablers indicated an overall positive level of information sharing.

The study points to largely echoed previous findings which suggest that individual work role associated tasks prompt particular information needs. Further to this, work role associated tasks have a bearing on information source selection. Pharmaceutical professionals engaged in positive levels of information and knowledge sharing, relying on procedures, other colleagues and internal documentation as information sources. The participants also indicated a high level of agreement in respect to the value of available subject matter experts as information-sharing enablers.

Organisations should aim to create opportunities for adequate time to share information and organisational structures, facilitating an overall organisational culture of sharing. A focus on information sharing through forums, seminars, meetings and working groups could enhance information sharing, through the development of communities of practice.

Pharmaceutical professionals relied on trustworthiness and quality as professional' top information source-influencing factors. Furthermore, the study demonstrated that working within a high-performance, target-driven and time-constrained production environment brings a particular contextual impact, where frequent urgent information triggers are experienced. These contextual factors warrant further investigation.

A paucity of information exists with respect to the ISB of professionals, working within the pharmaceutical manufacturing sector, which is a sector known for its high level of information use and production. This paper offered an original empirical investigation of the ISB of professionals, working within the pharmaceutical manufacturing sector in the Republic of Ireland, focussing on key professional tasks. The research also addressed the level of support available for knowledge and information sharing.

The purpose of this paper is to examine reported literature on the influence of medical representatives (MRs) and other promotional tools on drug prescribing behaviour, and to assess whether this effect is different in developed and developing countries.

A survey of the literature was conducted across online databases from 2000 to 2016. Eligible studies addressed MRs and other promotion tools used to influence drug prescribing in developed and developing countries.

A total of 40 reviewed studies met the inclusion requirements. In total, 22 of the studies were conducted in developed countries and 18 in developing countries. Out of ten studies that examined the influence of MRs on drug prescribing in developed countries, eight found a positive influence, one found only moderate and one finds no influence. Analogous results were found in developing countries. Six out of ten studies on the influence of MRs conducted in developing countries found a positive effect, three found only moderate effects, while one finds no influence. The influence of promotion tools on prescribing varied in developed countries, five found positive influence, four reported a small effect and one found negative influence. In developing countries, the size of effect also varied, five studies found positive influence of promotion tools on drug prescribing behaviour, five found a negligible or small effect, and one found no association. However, marked differences were observed between two sectors. In the developed countries, MRs are valued as a source of information and can have an effect on prescribing, while it is unreliable in developing countries. Sample drugs are more generally seen as an important promotional tool for prescribing in developed countries than developing countries.

The results derived from this review are based on studies with varying methodological consistency. The review provides the crucial information that will be valuable to researchers working on comparative analysis of marketing efforts in developing and developed countries.

This paper is one of the few systematic reviews on the influence of MRs and other promotional tools on prescribing. It compares the influence of MRs and promotional efforts in both developed and developing countries.

The purpose of this investigation is to add to the body of knowledge regarding consumer skepticism toward advertising in general, and toward pharmaceutical advertising in particular. The study was conducted in the U.S. and in Germany. Skepticism toward advertising for both prescription and non-prescription pharmaceuticals was analyzed. Additional variables explored include: health consciousness, product involvement with pharmaceuticals, satisfaction with information in pharmaceutical advertising, and the importance of pharmaceutical advertising as a source of information. Furthermore, differences in the cultural value of uncertainty avoidance between U.S. and German consumers were examined and related to skepticism toward pharmaceutical advertising. Three hundred and forty-one Americans and 447 Germans were surveyed. A significant finding of this research revealed that skepticism toward pharmaceutical advertising is lower than skepticism toward advertising in general. Results also indicated that consumers showed no difference in their level of skepticism toward advertising for prescription versus non-prescription drugs. This is a particularly relevant finding as it relates directly to the ongoing discussion in Europe regarding whether or not to lift the ban on advertising for prescription drugs. Skepticism toward pharmaceutical advertising was found to be significantly negatively related to involvement with pharmaceuticals, to satisfaction with the informational content of the advertisements, to satisfaction with the comprehensibility of the advertisements, and to the importance placed on advertising as a source of health information. Regarding cultural differences, U.S. consumers appear to be less skeptical toward advertising in general, and toward advertising for prescription and non-prescription drugs in particular, than German consumers. This may be due to the lower degree of uncertainty avoidance in the U.S. Differences between the two countries related to the additional variables examined in the study are addressed as well. Implications for consumer protection policies are discussed, and recommendations for advertisers of pharmaceutical products are provided. The authors provide a cultural explanation for differences in the degree of skepticism between U.S. and German audiences.

The pharmaceutical industry is a high‐technology, high‐investment and high‐risk industry. It is also a highly competitive research‐based industry and a dedicated and demanding user of information. It follows that the industry is in the forefront of information science and information handling techniques which use the new information technologies, both with respect to handling internally generated data and externally published materials.

This paper aims to examine the consistencies and discrepancies in corporate social responsibility (CSR) reporting by analyzing the CSR reports of pharmaceutical companies. Despite the major role pharmaceutical companies play in the CSR field, our knowledge of the extent to which their disclosures provide comprehensive, material, credible and accurate information on their actual performances is limited because of a lack of sufficient literature on the CSR reporting practices of pharmaceutical companies.

The authors present a literature review that serves as the basis to develop the two key research questions: Do pharmaceutical companies publish comprehensive CSR reports? Are company reports that cover more material issues more comprehensive? Using the information on material CSR topics provided by the Sustainability Accounting Standards Board (SASB) and CSR reporting quality scores by the CSR-Sustainability Monitor®, the authors analyzed the CSR reports of the world’s 15 leading pharmaceutical companies. A total of 11 material topics from SASB were mapped onto the corresponding contextual elements in the CSR-Sustainability Monitor. The Monitor evaluates CSR reports published by the world’s largest companies in terms of the degree of transparency and external verification of reporting.

The analyses revealed that while the pharmaceutical industry outperforms other industries in terms of the overall comprehensiveness of reporting, certain discrepancies exist among these companies in the content of their disclosures. Specifically, pharmaceutical companies beat the averages on multiple key CSR topics. However, while disclosures on mature areas such as environment and labor relations show some level of standardization, those focusing particularly on sensitive areas such as human rights and supply chain are far from being standardized. The authors also find that CSR reports that do not include all of SASB’s material topics are just as comprehensive as those that do. A detailed analysis of US and non-US companies separately further revealed that this result is valid for both groups of companies.

Considering the voluntary nature of CSR reporting, pharmaceutical companies still resort to selective disclosure techniques to highlight their achievements in areas where they feel more confident while leaving out others that can have potential negative consequences on the company. These results underscore the evolving nature of CSR reporting in the pharmaceutical industry and call for more attention and further investigation from managers and researchers alike.

The originality and value of the research show that despite its rapid growth and wide recognition by different segments of society and business as an effective and promising concept, CSR reporting has not yet reached a point where its expected benefits are realized. Focusing on the disclosure side of the story, this paper tries to identify the extent to which the pharmaceutical industry appropriately addresses increasing societal demand for enhanced transparency on its sustainable business policies and practices.

The purpose of this paper is to assess the quality of Tehran pharmacies' services and their impacts on the pharmaceutical firms, to highlight forces behind the current situation and suggest some improvements. This provides the means for pharmaceutical companies to differentiate themselves by quality of services, in the forefront of dealing with the customers, so‐called the last “touch point”.

After a comprehensive literature review, SERVQUAL model was chosen to be used in this study. A combination of quantitative and qualitative (integrative) methods was used for data collection and analysis. The quantitative data were gathered by questionnaires, including 22 pair items measuring expectation and perception, followed by qualitative data, including 32 in‐depth interviews. Furthermore, the views of our expert panel consisting of nine experts have been identical to the study. For statistical treatment of quantitative data, SPSS software was used.

The study reveals that Tehran community pharmacies are facing serious service quality problems. The results of quantitative data show negative gaps in perceptions and expectations of customers in all 22 SERQUAL statements and all dimensions: Information, Reliability, Empathy, Appearance and Time commitment. Comparatively, appearance dimension is ranked as the highest quality and the lowest rank belongs to information dimension. The findings show that the generic SERVQUAL scale does not properly measure the quality of pharmacies' services; therefore, the authors recommend an industry‐based scale; called PHARMA‐SERVQUAL. The findings show the reasons for low quality services are: low education of pharmacists' assistants, lack of proper regulation and control, pharmacies' economic problems and cost of quality improvement, the culture of blaming others and accusing pharmaceutical firms, government and social security organization. In short, pharmacists transfer their service problems to pharmaceutical firms, which have largely neglected this last touch point with the customer. The study also suggests some quality improvements and academic as well as managerial implications.

The study provides empirical evidence regarding the service quality of pharmacies in a developing country (Iran) and adds depth to the understanding of the reasons behind the quality problems. This research contributes to the understanding of how pharmacies' qualities of services enhance/change the customers' perception of the pharmaceutical companies' product qualities. It suggests that the firms should differentiate themselves at the pharmacies as the “last touch point” dealing with the end‐users. The study sheds light on the necessity of modifying the SERVQUAL items and dimensions to fit pharmacies' services.

The purpose of this paper is to assess the state of the art in social media and pharmaceutical marketing through empirical analysis of online consumer conversations. Proliferation of social media has significantly changed traditional one-way, marketing-controlled communications. Balance of power has shifted to consumers, who use social networking sites, blogs and forums to obtain extensive brand and product information, often from each other. This prompts companies towards more intimate, transparent and constant two-way consumer engagement. Pharmaceutical marketing and direct to consumer advertising (DTCA) are not immune to this pervasive, disruptive cultural/technological phenomenon, which poses particular challenges given regulatory, legal and ethical constraints on their marketing.

This research uses “netnographic” data collection of online conversations occurring in social media and develops an explanatory framework using grounded theory analytical methods.

This research shows that significantly impactful and pervasive bonding among consumers, bloggers and unofficial “experts” about pharmaceutical offerings is widespread, and occurs regardless (and perhaps in spite of) pharmaceutical companies’ involvement.

Considering the structure and nature of online consumer bonding, a way forward is proposed for pharmaceutical companies to implement social media strategies as part of their pharmaceutical marketing and DTCA efforts through an intermediary and interactive online presence arising from disease and health care education.

Purpose – This chapter explores the pharmaceutical industry's strategic utilization of empowerment discourse in two realms: direct-to-consumer advertising (DTCA) and clinical drug development.

Methodology – It draws upon two research projects that examine the role of the pharmaceutical industry in the political economy of healthcare in the United States: Ronald's policy analysis and participant observation of DTCA policy hearings and Fisher's participant observation and interviewing of the clinical trials industry.

Findings – Empowerment rhetoric is mobilized by the pharmaceutical industry to create specific expectations about patient-consumer behavior, particularly the responsibilities associated with the consumption of drugs.

Research implications – The social and economic implications of DTCA and drug trials must be understood within their broader historical and contemporary contexts of health advocacy, consumerism, and medical neoliberalism.

Practical implications – The chapter offers alternative constructions of healthcare subjects and pharmaceutical practices that can mitigate the power of the pharmaceutical industry and bring about better pharmaceutical governance.

Originality/value of chapter – By analyzing findings from two empirical projects, this chapter is able to shed light on trends in the pharmaceutical industry's discourse about empowerment and consumption from the clinical testing to marketing of new drugs.

A review was carried out of the ‘information landscape’ within the pharmaceuticals‐based molecular biology community, which examined the research problems requiring biological‐sequence data, important sources of information, methods of access, information‐seeking behaviour of end users and the role of libraries and information centres. This work concentrated on the practical aspects of how biological sequence information is managed and used in a research setting and was carried out as part of the MSc in Information Science at the City University. Fifteen questionnaires were sent to information scientists in the UK pharmaceutical industry and a user study was carried out amongst scientists at Celltech. Most of the important primary data are available freely or cheaply via the Internet and molecular biologists were found to be self‐reliant in their use of these resources. Currency of information was found to be very important in the research process and the issue of Internet security was taken very seriously. Most questionnaire respondents saw a productive role in the future for information workers in the field of molecular biology, citing end‐user training and data integration as possible roles, although the degree of involvement will depend on the particular mix of skills and experience that exist within an information department.

Drugs and pharmaceuticals assume importance in the healthcare system today for their capacity to replace costly treatments like surgery. The pharmaceutical industry is considered capital intensive and building a new product costs as much as $900 million. Though the cost of developing a new product is significantly low in a country like India, it is substantial. Therefore, perhaps, companies try to go for incremental innovation. This apart, finding new symptoms to promote products, hiding major side effects, publishing data mixing the outcomes of different studies, publishing major outcomes in reputed journals and poor outcome studies in less important journals are some of the strategies being adopted by pharmaceutical companies. The purpose of this paper is to analyze these issues and their impacts on the Indian economy. As most of the Indian pharmaceutical companies are in private hands, this paper focuses on the possible plight of Indian poor in the changing world order.

This paper draws upon earlier research undertaken by the author. His experience from the pharmaceutical industry as well as the published works of other researchers also helped complete the work.

The analysis of this paper indicates that in order to avoid the loss of revenue and to keep their businesses floating, drug and pharmaceutical companies resort to information manipulation.

The research is limited to the author's ability to review literatures in the field of marketing and corporate ethics related to drugs and pharmaceuticals. As competition and economic liberalization would have a significant impact on pharmaceutical brand‐success, therefore, perhaps, drug companies would resort to manipulations for survival. This paper is an attempt to alert the society to these sorts of information laundering.

This paper would perhaps provide consumers with necessary information to understand the unethical practices being adopted by drug companies and help them consider what exactly to look for and would press for their right to good health.

This paper is the record of original work done by the author. It would probably fulfil an identified need and would perhaps help the society fight unethical practices being adopted by pharmaceutical companies.